Specific lots of intravenous immune globulin (IVIG) and subcutaneous IG (SCIG) have been voluntarily withdrawn by the manufacturers due to a higher rate of allergic/hypersensitivity type reactions, some of which were considered medically significant.
Grifols announced positive results from its Phase II/III clinical trial evaluating the efficacy and safety of Flebogamma 5% DIF (intravenous immune globulin [IVIG]) to treat patients with post-polio syndrome, which demonstrated a significant improvement in distance walked compared to placebo.
A new study published in the journal Nature found that a personalized vaccine, named autogene cevumeran, is showing promising results for treating pancreatic cancer, one of the deadliest malignancies.
Chinese researchers have developed a “cocktail” nanovaccine to prevent plaque from building up in the arteries, an underlying factor in heart disease, which is the leading cause of death worldwide.
Scientists at the University of Cambridge, who have been investigating how certain common medications might hold back the movement of cancer cells, have found that daily low-dose aspirin use could curb the spread of certain cancers, including breast and prostate tumors.
A recent study found there is significantly higher intravenous immune globulin (IVIG) resistance among children who contracted COVID-19 before developing Kawasaki disease (KD).
The U.S. Food and Drug Administration (FDA) has approved VIMKUNYA (chikungunya vaccine, recombinant) for injection, the first virus-like particle (VLP) single-dose chikungunya vaccine in the U.S. for persons 12 years of age and older.
GSK’s Penmenvy (meningococcal groups A, B, C, W and Y vaccine) has been approved by the U.S. Food and Drug Administration (FDA) for use in individuals aged 10 through 25 years.
Findings of a Phase III randomized controlled trial showed Pfizer’s RSV Prefusion F (RSVpreF) vaccine triggered strong immune responses among people aged 60 years and older during its first two seasons.
Celltrion’s Avtozma (tocilizumab-anoh), a biosimilar to Actemra (tocilizumab), in both intravenous and subcutaneous formulations, has been approved by the U.S. Food and Drug Administration.
The U.S. Food and Drug Administration has approved Vertex Pharmaceutical’s Journavx (suzetrigine), a new type of prescription pain medication for adults to treat moderate to severe acute pain.
Results of a recent study show patients with multiple myeloma undergoing teclistamab therapy may benefit from primary intravenous immune globulin supplementation, which appears to reduce the risk of high-grade infection.
